ID   FB-2
AC   CVCL_9917
SY   FB2
DR   BioSample; SAMN03151972
DR   Cosmic; 1084278
DR   IARC_TP53; 25010
DR   Wikidata; Q54833256
RX   PubMed=11807785;
RX   PubMed=17725429;
RX   PubMed=19087340;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a TPC-1 derivative (PubMed=19087340; PubMed=20143388). Originally thought to originate from a 36 year old female patient with a well-differentiated thyroid papillary carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00200.
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6298 ! TPC-1
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 23
//
RX   PubMed=11807785; DOI=10.1002/ijc.10116;
RA   Basolo F., Giannini R., Toniolo A., Casalone R., Nikiforova M.,
RA   Pacini F., Elisei R., Miccoli P., Berti P., Faviana P., Fiore L.,
RA   Monaco C., Pierantoni G.M., Fedele M., Nikiforov Y.E., Santoro M.,
RA   Fusco A.;
RT   "Establishment of a non-tumorigenic papillary thyroid cell line (FB-2)
RT   carrying the RET/PTC1 rearrangement.";
RL   Int. J. Cancer 97:608-614(2002).
//
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
//
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//